An experimental gene therapy known as GC301 improved motor function and cardiac outcomes for three out of four infants with infantile-onset Pompe disease (IOPD) in a small clinical trial. The treatment was also well tolerated. One year after treatment, these three participants had reached milestones such as…
GC301
Recent Posts
- 1-time gene therapy cuts need for enzyme treatments for Pompe children
- What a child with Pompe disease taught me about being a parent
- Switching therapies may stabilize walking decline in late-onset Pompe
- How I’m coping with mom guilt since my daughter’s Pompe diagnosis
- ERT helps keep breathing stable during sleep in pediatric Pompe disease